14 April 2022 in AI and Ethics
Persuasive online technologies were initially designed and used to gain insights into the online behavior of individuals to personalize advertising campaigns in an effort to influence people and convince them to buy certain products. But recently, these technologies have blurred the lines and morphed into technologies that covertly and gradually manipulate people into attaining a goal that is predetermined by the algorithm and disregards the decision-making rights of the individual. This may lead to people exercising decisions that do not align with their personal values and beliefs, and rob them of their autonomy—an ethical principle, in the absence of which the application of these technologies may be unethical. However, not all technologies that are persuasive are necessarily manipulative which require the careful consideration of a couple of elements to determine whether or not technologies are manipulative and ultimately whether their application is ethical or not. In this article, we analyze the ethical principle of autonomy and unpack the underlying elements of this ethical principle which must be considered to determine whether the application of a technology is ethical or not in the context of it being persuasive or manipulative.
28 November 2022 in PLOS ONE
This paper reports the results of a public engagement study on heritable human genome editing (HHGE) carried out in South Africa, which was conducted in accordance with a study protocol that was published in this journal in 2021. This study is novel as it is the first public engagement study on HHGE in Africa. It used a deliberative public engagement (DPE) methodology, entailing inter alia that measures were put in place to ensure that potential participants became informed about HHGE, and that deliberations between the participants were facilitated with the aim of seeking consensus. A diverse group of 30 persons was selected to participate in the DPE study, which took place via Zoom over three consecutive weekday evenings. The main results are: Provided that HHGE is safe and effective, an overwhelming majority of participants supported allowing the use of HHGE to prevent genetic health conditions and for immunity against TB and HIV/Aids, while significant majorities opposed allowing HHGE for enhancement. The dominant paradigm during the deliberations was balancing health benefits (and associated improvements in quality of life) with unforeseen health risks (such as loss of natural immunity). The seriousness of a health condition emerged as the determining factor for the policy choice of whether to allow an application of HHGE. More generally, equal access to HHGE qua healthcare service featured as an important value, and it was uncontested that the South African government should allocate resources to promote scientific research into HHGE. These results are aligned with the policy principles for regulating HHGE in South Africa suggested by Thaldar et al. They call for urgent revision of South African ethics guidelines that currently prohibit research on HHGE, and for dedicated HHGE legal regulations that provide a clear and comprehensive legal pathway for researchers who intend to conduct HHGE research and clinical trials.
28 June 2019 in South African Medical Journal
Safeguarding the future of genomic research in South Africa: Broad consent and the Protection of Personal Information Act No. 4 of 2013
30 April 2025 in Frontiers in Pharmacology
Introduction: This study explores the regulatory challenges posed by digital mental health applications in South Africa, particularly regarding the collection and protection of personal data. It aimed to assess whether South Africa’s current legal framework sufficiently protects users’ sensitive mental health data amidst the rise of digital mental health solutions, especially in the context of privacy concerns.Methods: The research focused on the intersection of digital mental health applications, data protection laws, and user privacy in South Africa. It examined existing legal frameworks, including the Protection of Personal Information Act (POPIA), National Health Act (NHA), and Consumer Protection Act (CPA). The study reviewed relevant literature, legal texts, and case studies, focusing on mental health applications in both urban and rural contexts.Results: While South Africa has laws in place to protect personal information, these laws have significant gaps in addressing the unique risks associated with digital mental health technologies. Key findings include inadequate regulation of AI-driven mental health tools, insufficient guidelines for third-party data sharing, and challenges with cross-border data transfers.Discussion: The implications of these findings suggest that South Africa needs to modernize its legal framework to better regulate digital mental health tools and ensure user privacy. This includes improving AI regulation, strengthening consent mechanisms, and enhancing protections against third-party data misuse. Future research should focus on developing specific legal guidelines for mental health data and addressing the vulnerabilities faced by rural populations with low digital literacy. The study’s conclusions align with global concerns over the ethical implications of mental health datacommodification and emphasize the need for robust, adaptable regulatory approaches.
29 September 2020 in South African Journal of Science
Human germline editing holds much promise for improving people’s lives, but at the same time this novel biotechnology raises ethical and legal questions. The South African ethics regulatory environment is problematic, as it prohibits all research on, and the clinical application of, human germline editing. By contrast, the South African legal regulatory environment allows a regulatory path that would, in principle, permit research on human germline editing. However, the legal regulation of the clinical application of human germline editing is uncertain. As such, the current ethical and legal positions in South Africa are in need of reform. Five guiding principles – aligned with the values of the Constitution – are proposed to guide ethical and legal policy reform regarding human germline editing in South Africa: (1) Given its potential to improve the lives of the people of South Africa, human germline editing should be regulated, not banned. (2) Human germline editing clinical applications should only be made accessible to the public if they are proven to be safe and effective. (3) Non-therapeutic human germline editing may be permissible, and should be regulated in the same way as therapeutic human germline editing. (4) The decision on whether to use germline gene editing on a prospective child, should, subject to Principle 2, be left to the prospective parents. (5) Concerns about exacerbating social inequalities should be addressed by measures to increase access. In conclusion, recommendations are made to policymakers and scientists contemplating research in this field. Significance: The ethical and legal positions regarding human germline editing in South Africa are comprehensively analysed. Furthermore, five guiding principles – aligned with the values of the Constitution – are proposed to guide much needed ethical and legal policy reform regarding human germline editing in South Africa.
3 September 2020 in BMC Medical Ethics
Background: Whenever South African (SA) research institutions share human biological material and associated data for health research or clinical trials they are legally compelled to have a material transfer agreement (MTA) in place that uses as framework the standard MTA newly gazetted by the South African Minister of Health (SA MTA). Main body: The article offers a legal analysis of the SA MTA and focuses on its substantive fit with the broader legal environment in South Africa, and the clarity and practicality of its terms. The following problematic aspects of the SA MTA are highlighted: (a) Where only data and no human biological material are transferred, the SA MTA does not apply, leaving a lacuna; (b) Health Research Ethics Committees are required to be parties to a MTA despite it being outside their legal mandate and undermining their oversight function; (c) the SA MTA’s consent provisions are not aligned with extant law; and, similarly, (d) its provision on donor ownership is misaligned with extant law; (e) its creation of fictitious performance can only cause frustration on the part of an injured party; (f) its benefit-sharing provision is vague and will have little practical effect; (g) its dispute-resolution provisions fail to adequately protect South African research institutions and research participants; (h) it fails to provide substantive guidance regarding intellectual property as its provisions relating to intellectual property may cause practical problems; and, finally, (i) its data privacy provision is insufficiently specific, is overbroad, and fails to provide terms that in general would facilitate the international sharing of human biological material and associated data in terms of existing privacy law. Conclusions: While some of the problematic aspects of the SA MTA are intricate and require consultative processes with stakeholders and others, to develop comprehensive solutions, most of the problematic aspects can be resolved immediately through amendments by the South African Minister of Health. The formulation of such amendments is proposed and, where possible, interim measures are suggested that may ameliorate the problems presented by the SA MTA.